Some Cardiovascular magnetic resonance (CMR) studies investigated the long term effects of cancer treatments, but were never applied to the detection of early changes during cardiotoxicity remodelling. The CMR parameters we investigated in the miniature swine therapeutic model with doxorobucin was able discriminate treated animals from controls. Differences were detectible earlier than onset of classical echocardiographic changes. Translating these observations to personalized medicine approach could be the premise for the oncologist to know accurately when the treatment just starts to have deleterious effect on myocardium instead of just observing that the heart was damaged by doxorubicin.
This abstract and the presentation materials are available to members only; a login is required.